French pharmaceutical giant Sanofi (NASDAQ: SNY ) is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics (NASDAQ: MRTX ), according to a report from Bloomberg, which cited people familiar with the matter. As a result, Mirati shares jumped more than 38% intra-day today.
The sources noted that discussions are ongoing, and there is no assurance that they will lead to a formal agreement. Additionally, Mirati may attract interest from other potential buyers.
Both Mirati's and Sanofi’s spokespersons declined to comment on the matter.
Mirati is in the process of introducing its first product, Krazati, to patients. This drug is used as a second-line treatment for a specific type of lung cancer characterized by a mutated KRAS gene. The Food and Drug Administration granted accelerated approval for Krazati in December.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.